Autoantibodies and defined target autoantigens in autoimmune hepatitis: An overview

European Journal of Internal Medicine

Volumn 13, Issue 5, 2002, Pages 293-303

  Dalekos, G N ^a,b   Zachou, K ^a   Liaskos, C ^a   Gatselis, N ^a  

^a Larisa Medical School   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Antibodies to liver cytosol 1 antigen (anti LC1); Antibodies to soluble liver antigens or liver pancreas (anti SLA LP); Antinuclear antibodies (ANA); Autoimmune hepatitis; Cytochrome P450 complex; Liver kidney microsomal autoantibodies (anti LKM); Smooth muscle autoantibodies (SMA)

Indexed keywords

ALPHA INTERFERON; ANTIGEN; ANTINUCLEAR ANTIBODY; ANTIPERINUCLEAR FACTOR; ASIALOGLYCOPROTEIN RECEPTOR; AUTOANTIBODY; AUTOANTIGEN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEAMINASE; DIHYDRALAZINE; FORMIMINOTRANSFERASE CYCLODEAMINASE; GLUCURONOSYLTRANSFERASE; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; KIDNEY ANTIBODY; KIDNEY ANTIGEN; LIVER ANTIGEN; LIVER ENZYME; MARKER; NEUTROPHIL CYTOPLASMIC ANTIBODY; SMOOTH MUSCLE ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE HEPATITIS; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CHRONIC HEPATITIS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; GENETIC DISORDER; HEPATITIS; HEPATITIS C; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL DAMAGE; LIVER CELL MEMBRANE; LIVER CYTOSOL; PROTEIN EXPRESSION; REVIEW; VIRUS HEPATITIS;

EID: 0036322794     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-6205(02)00089-4     Document Type: Review

References (121)

1. Autoimmune hepatitis: clinical challenges
2. Drug therapy in the management of type 1 autoimmune hepatitis
3. Incidence and prevalence of autoimmune liver diseases
4. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population
5. Autoimmune hepatitis
6. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis
7. Can you recognize autoimmune hepatitis?
8. Present status of autoimmune hepatitis in Japan-correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis
9. Type I autoimmune hepatitis is primarily a disease of later life
10. Autoimmune hepatitis in the elderly
11. Clinical features of 89 patients with autoimmune hepatitis in Nagasaki Prefecture
12. Meeting report of the International Autoimmune Hepatitis Group
13. Classification of chronic hepatitis: diagnosis, grading and staging
14. Chronic active hepatitis associated with anti-liver kidney microsome antibody type I: a second type of 'autoimmune hepatitis'
15. Antibody to liver cytosol (anti-LC1) in patients with autoimmune hepatitis type 2
16. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against soluble liver antigen
17. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis
18. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains
19. Positional cloning of the APECED gene
20. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients
21. The autoimmune polyglandular syndromes
22. The validity and importance of subtypes in autoimmune hepatitis: a point of view
23. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis
24. Antibodies to soluble liver antigen: an additional marker in type 1 autoimmune hepatitis
25. Autoimmune hepatitis in childhood: a 20 year experience
26. Autoimmune hepatitis type 2 and hepatitis C virus infection: study of HLA antigens
27. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis
28. Identification of Cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic diseases
29. Antibodies to single stranded and double-stranded DNA in antinuclear antibody-positive type 1 autoimmune hepatitis
30. Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association
31. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis
32. Immunologic and viral markers in anti-HIV negative heroin addicts
33. Immunological markers (cytokines, receptors and autoantibodies) in chronic active hepatitis (CAH) due to hepatitis B virus (HBV): prognostic factors and interrelations during therapy with interferon-a (IFN-a)
34. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on disease profile
35. Dermatologic disease during interferon-alpha therapy for chronic viral hepatitis
36. Increased incidence of anticardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to antiphospholipid syndrome
37. Behaviour and significance of autoantibodies in type 1 autoimmune hepatitis
38. Autoantibodies against neutrophils and monocytes tool for diagnosis and marker of disease activity in Wegener's granulomatosis
39. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis
40. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies and other autoantibodies in patients with ulcerative colitis
41. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis
42. Anti-neutrophil cytoplasmic antibody: a prognostic indicator in primary sclerosing cholangitis
43. High titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis
44. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases
45. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins
46. Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases
47. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis
48. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases
49. Antineutrophil antibodies in chronic viral hepatitis
50. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases
51. High mobility group (HMG) non-histone chromosomal proteins HMG1 and HMG2 are significant target antigens of perinuclear anti-neutrophil cytoplasmic antibodies in autoimmune hepatitis
52. Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1
53. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis
54. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis
55. Antibodies against the hepatic asialoglycoprotein receptor perfused in situ preferentially attach to periportal liver cells in the rat
56. Pathogenesis of autoimmune hepatitis
57. Characterization of liver cytokeratin as a major target antigen of anti-SLA antibodies
58. Cytoplasmic autoantigens in autoimmune hepatitis: Molecular analysis and clinical relevance
59. Antibodies to soluble liver antigen: specific marker of autoimmune hepatitis
60. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis
61. Members of the glutathione S-transferase gene family are antigens in autoimmune hepatitis
62. Isolation and characterization of a cDNA clone encoding a gene product recognising anti-SLA/LP sera in autoimmune hepatitis
63. Autoantibodies in liver disease
64. Targets proteins in human autoimmunity: cytochromes P450 and UDP-glucuronosyltransferases
65. Human antiendoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis directed against a human liver cytochrome P450 that hydroxylates the drug
66. Microsomal antibodies in active chronic hepatitis and other disorders
67. The major target antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 db1
68. Anti-liver kidney microsome antibody type 1 recognizes cytochrome P450 db1
69. Antibodies against human cytochrome P450 db1 in autoimmune hepatitis type 2
70. Patients with type II autoimmune hepatitis express functionally intact cytochrome P450 db1 that is inhibited by LKM1 autoantibodies in vitro but not in vivo
71. LKM-1 autoantibodies recognize a short linear sequence in P450 2D6, a cytochrome P450 monooxygenase
72. Identification and analysis of cytochrome P450 2D6 antigenic sites recognized by anti-liver kidney microsome type-1 antibodies (LKM1)
73. Overlapping but distinct specificities of anti-liver-kidney microsomes antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes
74. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies
75. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C
76. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C
77. Non-organ specific autoantibodies in children with chronic hepatitis C
78. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of HCV patients from central Greece
79. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay
80. Establishment of a novel radioligand assay using eukaryotically expressed cytochrome P4502D6 for the measurement of liver kidney microsomal type-1 antibody in patients with autoimmune hepatitis and hepatitis C virus infection
81. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C
82. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease
83. Differences in immune recognition of cytochrome P450 2D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection
84. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera
85. Liver/kidney microsome antibody type 1 and hepatitis C virus infection
86. Chronic hepatitis C associated with anti-liver/kidney microsome-1 antibody is not a subgroup of autoimmune hepatitis
87. Autoimmune chronic active hepatitis type 2 manifested during interferon therapy in children
88. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C
89. Efficacy and safety of interferon alpha therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes
90. Epitope mapping of cytochrome P450 2D6 autoantigen in patients with chronic hepatitis C under α-interferon treatment
91. Discordant manifestation of LKM-1 antibody positive autoimmune hepatitis in identical twins
92. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis
93. Development of cytochrome P450 2D6 specific LKM-autoantibodies following liver transplantation for Wilson's disease: possible association with a steroid-resistant transplant rejection episode
94. Yeast expressed cytochrome P450 2D6 (CYP2D6) exposed on the external face of plasma membrane is functionally competent
95. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane
96. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis
97. T cell receptor Vbeta chain restriction and preferred CDR3 motifs of liver-kidney microsomal antigen (LKM-1)-reactive T cells from autoimmune hepatitis patients
98. Human antiendoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis directed against a human liver cytochrome P450 that hydroxylates the drug
99. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis
100. LKM-3 autoantibodies in chronic hepatitis D recognize the UDP-glucuronosyl-transferases
101. Microsomal autoantibodies in chronic infection with HBsAg associated delta (d) agent
102. LKM3 autoantibodies in hepatitis C cirrhosis: a further phenomenon of the HCV-induced autoimmunity
103. Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases
104. Characterization of liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis
105. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection
106. Formininotransferase cyclodeaminase is organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis
107. Argininosuccinate lyase: a new autoantigen in liver disease
108. Hepatitis C and D, retroviruses and autoimmune manifestations
109. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis
110. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
111. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1
112. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1
113. Cytochrome P450IA2 and aromatic L-amino acid decarboxylase are hepatic autoantigens in autoimmune polyendocrine syndrome type I
114. Antibodies against cytochrome P4502A6 (CYP2A6) in patients with chronic viral hepatitis (CVH) are mainly linked to hepatitis C virus (HCV) infection
115. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P450 IA2: a specific marker of dihydralazine-induced hepatitis
116. Autoantibodies against cytochromes P450: role in human diseases
117. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure
118. Aromatic-L-aminoacid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigen
119. Autoimmune hepatitis: the investigational and clinical challenges
120. Understanding the pathogenesis of autoimmune hepatitis